TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01700322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: All patients will receive a drug eluting stent as clinically indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: All patients will receive a drug eluting stent as clinically indicated.
Study: NCT02004327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M600mg
Description: DW1029M300mg 2 tablets Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M1200mg
Description: DW1029M300mg 4 tablets PO Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M1200mg
Description: DW1029M300mg 4 tablets PO Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M1200mg
Description: DW1029M300mg 4 tablets PO Once
Study: NCT04140916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline catheter
Description: Peripherally inserted short intravenous catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC-line catheter
Description: Peripherally inserted long intravenous catheter
Study: NCT02305446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
Study: NCT02974920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban 10 mg once daily for 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 180 days
Study: NCT01272375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-04764793 250/50 using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: PF-04764793 250/50 using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: PF-04764793 250/50 using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: PF-04764793 250/50 using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: PF-04764793 250/50 using inhaler B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: PF-04764793 250/50 using inhaler B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: PF-04764793 250/50 using inhaler B
Study: NCT00851019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DDR
Description: Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Ad libitum attendance to engage in treadmill exercise, for a 3-month period
Study: NCT01156051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release tablets
Description: Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
Study: NCT02262416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide
Description: normal saline
Study: NCT01627782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
Study: NCT01700322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
Study: NCT01006499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
Study: NCT02815059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
Study: NCT01143545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Tumor Cell Vaccine (K562)
Description: Subcutaneous injection monthly for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 g po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg po bid
Study: NCT04049370

Intervention type: OTHER
Intervention: No intervention
Description: Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit.
Study: NCT04339023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo
Description: in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)

Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
Study: NCT02273700

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
Study: NCT00078949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT00768339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEG35156 antisense IV infusion
Description: AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion
Study: NCT02627898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules, 400mg 1 time daily with the first bite of eat meal
Study: NCT03984175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Processes
Description: Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
Study: NCT03895502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-month Edoxaban
Description: Prescription of Edoxaban for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-month Edoxaban
Description: Prescription of Edoxaban for 3 months
Study: NCT03247738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
Study: NCT00129649

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder call
Study: NCT02802150

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zanthoxylum Schinifolium Seed Oil(4g/day)
Description: parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Bean Oil;placebo(4g/day)
Description: parallel design
Study: NCT02906475

Intervention type: OTHER
Group type: OTHER
Intervention: standardized skin care regimen
Description: Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed
Study: NCT01582503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study: NCT05383625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: intralesional 0.1 ml every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalent Human Papilloma Virus Vaccine
Description: Intralesional 0.1 ml every two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intralesional into the largest warts every two weeks
Study: NCT02767609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
Study: NCT05509686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Description: The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
Study: NCT03108872

Intervention type: DEVICE
Intervention: left atrial appendage occlusion
Description: Percutaneous exclusion of left atrial appendage with Watchman or ACP devices

Intervention type: DRUG
Intervention: New oral anticoagulants
Description: Include dabigatran, rivaroxaban, apixaban and edoxaban
Study: NCT03727295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone/placebo
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone/placebo
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idebenone/placebo
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
Study: NCT03197740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch
Description: Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aricept Tab
Description: Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aricept Tab
Description: Comparator
Study: NCT01429974

Intervention type: OTHER
Intervention: amniometer model po1
Description: The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform.
Study: NCT03197077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound scanning
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound scanning
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte retrieval for IVM
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oocyte retrieval for IVM
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: Single injection of 100 micrograms of corifollitropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: Daily injection (three days) of follitropin beta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive pill pretreatment (Marvelon)
Description: Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pill pretreatment (Marvelon)
Description: Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
Study: NCT01658904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT02246218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAVICTI
Study: NCT04068051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07
Description: AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
Study: NCT02011217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread A
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread A
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread B
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread B
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat crisp bread C
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat crisp bread C
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
Study: NCT03551431

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video EEG with verbal suggestion
Description: Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video EEG with verbal suggestion
Description: Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video EEG with verbal suggestion
Description: Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
Study: NCT01946555

Intervention type: DRUG
Intervention: Morphine

Intervention type: DRUG
Intervention: Fentanyl

Intervention type: DRUG
Intervention: Methadone

Intervention type: DRUG
Intervention: Buprenorphine

Intervention type: DRUG
Intervention: Oxycodone

Intervention type: DRUG
Intervention: Hydromorphone

Intervention type: DRUG
Intervention: Tapentadol
Study: NCT01377168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study: NCT01217619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg/d continuously for 56 days